{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:39:17Z","timestamp":1787693957232,"version":"build-2784847793"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused by\n                    <jats:italic>Survival Motor Neuron 1<\/jats:italic>\n                    (\n                    <jats:italic>SMN1<\/jats:italic>\n                    ) gene mutations, leading to reduced SMN protein levels and progressive motor neuron (MN) degeneration. Although current therapies aim to restore SMN expression, limitations highlight the need for alternative strategies. We investigated haloperidol (HALO), a classical antipsychotic, as a potential therapeutic based on its ability to enhance\n                    <jats:italic>SMN2<\/jats:italic>\n                    splicing and SMN expression. Using the delta 7 SMA mouse model, we assessed effects of HALO on survival, motor function, neuroprotection, and neuroinflammation, by histological, molecular, and RNA-sequencing analyses of spinal cord and muscle samples. Additionally, we examined patient induced pluripotent stem cell-derived MNs and myotube co-cultures for validation in human cells. HALO increased lifespan and motor performance in mice with SMA, upregulated SMN protein in spinal cord and muscles, reduced MN loss, and attenuated neuroinflammation. Moreover, HALO enhanced neuromuscular junction integrity and muscle trophism, suggesting peripheral benefits. RNA-sequencing analysis revealed extensive splicing changes, including SMN target transcripts, supporting enhanced activity. In human models, HALO improved MN survival and SMN expression, supporting dual SMN-dependent and neuroprotective mechanisms. Given its central nervous system penetrance and clinical approval, HALO emerges as a promising SMA therapy candidate, warranting further dose optimization and validation for translational potential.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01689-0","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:24:42Z","timestamp":1776068682000},"page":"1216-1229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1141-329X","authenticated-orcid":false,"given":"Giovanna","family":"Menduti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Perez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Berenger-Currias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ruatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Espinosa-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Januel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Konieczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Artero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Martinat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Boido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"FNL25","DOI":"10.2217\/fnl-2019-0006","volume":"14","author":"JM Hoolachan","year":"2019","unstructured":"Hoolachan, J. M., Sutton, E. R. & Bowerman, M. Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy. Future Neurol 14, FNL25 (2019).","journal-title":"Future Neurol"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"592234","DOI":"10.3389\/fphar.2020.592234","volume":"11","author":"G Menduti","year":"2020","unstructured":"Menduti, G., Ras\u00e0, D. M., Stanga, S. & Boido, M. Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment. Front Pharmacol 11, 592234 (2020).","journal-title":"Front Pharmacol"},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155\u2013165 (1995).","journal-title":"Cell"},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri, E., Pera, M. C., Scoto, M., Finkel, R. & Muntoni, F. Spinal muscular atrophy \u2014 insights and challenges in the treatment era. Nat Rev Neurol 16, 706\u2013715 (2020).","journal-title":"Nat Rev Neurol"},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/hmg\/9.3.333","volume":"9","author":"UR Monani","year":"2000","unstructured":"Monani, U. R. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn\u2212\/\u2212 mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9, 333\u2013339 (2000).","journal-title":"Hum Mol Genet"},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"e000164","DOI":"10.1136\/bmjno-2021-000164","volume":"3","author":"WD Arnold","year":"2021","unstructured":"Arnold, W. D. et al. Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen. BMJ Neurol Open 3, e000164 (2021).","journal-title":"BMJ Neurol Open"},{"key":"1689_CR7","doi-asserted-by":"publisher","unstructured":"Rindt, H. et al. Astrocytes influence the severity of spinal muscular atrophy. Hum Mol Genet https:\/\/doi.org\/10.1093\/hmg\/ddv148 (2015).","DOI":"10.1093\/hmg\/ddv148"},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1523\/JNEUROSCI.3534-15.2016","volume":"36","author":"C Zhou","year":"2016","unstructured":"Zhou, C., Feng, Z. & Ko, C.-P. Defects in motoneuron\u2013astrocyte interactions in spinal muscular atrophy. J Neurosci 36, 2543\u20132553 (2016).","journal-title":"J Neurosci"},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.nbd.2020.104870","volume":"140","author":"E Abati","year":"2020","unstructured":"Abati, E., Citterio, G., Bresolin, N., Comi, G. P. & Corti, S. Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol Dis 140, 104870 (2020).","journal-title":"Neurobiol Dis"},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/NEN.0000000000000078","volume":"73","author":"R Mart\u00ednez-Hern\u00e1ndez","year":"2014","unstructured":"Mart\u00ednez-Hern\u00e1ndez, R., Bernal, S., Alias, L. & Tizzano, E. F. Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy. J Neuropathol Exp Neurol 73, 559\u2013567 (2014).","journal-title":"J Neuropathol Exp Neurol"},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI131989","volume":"130","author":"J-K Kim","year":"2020","unstructured":"Kim, J.-K. et al. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models. J Clin Invest 130, 1271\u20131287 (2020).","journal-title":"J Clin Invest"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1096\/fj.201802554RRR","volume":"34","author":"P Konieczny","year":"2020","unstructured":"Konieczny, P. & Artero, R. Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. FASEB J 34, 3021\u20133036 (2020).","journal-title":"FASEB J"},{"key":"1689_CR13","doi-asserted-by":"publisher","unstructured":"Januel, C. et al. Moxifloxacin rescues SMA phenotypes in patient\u2011derived cells and animal model. Cell Mol Life Sci https:\/\/doi.org\/10.1007\/s00018-022-04450-8 (2022).","DOI":"10.1007\/s00018-022-04450-8"},{"key":"1689_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14884-y","volume":"11","author":"L Fan","year":"2020","unstructured":"Fan, L. et al. Haloperidol bound D(2) dopamine receptor structure inspired the discovery of subtype selective ligands. Nat Commun 11, 1074 (2020).","journal-title":"Nat Commun"},{"key":"1689_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0254-6272(13)60026-6","volume":"32","author":"H Lv","year":"2012","unstructured":"Lv, H. et al. Effects of ningdong granule on DA, DRD2, and HVA in a rat model of Tourette\u2019s syndrome. J Trad Chinese Med 32, 283\u2013288 (2012).","journal-title":"J Trad Chinese Med"},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.12659\/MSM.895739","volume":"22","author":"S Yamamoto","year":"2016","unstructured":"Yamamoto, S. et al. Haloperidol suppresses NF-kappaB to inhibit lipopolysaccharide-induced pro-inflammatory response in rAW 264 cells. Med Sci Monit 22, 367\u2013372 (2016).","journal-title":"Med Sci Monit"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/BF03026824","volume":"20","author":"K Ishiwata","year":"2006","unstructured":"Ishiwata, K. et al. A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med 20, 569\u2013573 (2006).","journal-title":"Ann Nucl Med"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","volume":"14","author":"TT Le","year":"2005","unstructured":"Le, T. T. et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14, 845\u2013857 (2005).","journal-title":"Hum Mol Genet"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.expneurol.2008.02.025","volume":"212","author":"BF El-Khodor","year":"2008","unstructured":"El-Khodor, B. F. et al. Identification of a battery of tests for drug candidate evaluation in the SMN\u03947 neonate model of spinal muscular atrophy. Exp Neurol 212, 29\u201343 (2008).","journal-title":"Exp Neurol"},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jneumeth.2012.06.020","volume":"209","author":"BF El-Khodor","year":"2012","unstructured":"El-Khodor, B. F. et al. Prediction of death in the SMN\u03947 mouse model of spinal muscular atrophy: insight into disease stage and progression. J Neurosci Methods 209, 259\u2013268 (2012).","journal-title":"J Neurosci Methods"},{"key":"1689_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2018.00308","volume":"11","author":"R Schellino","year":"2018","unstructured":"Schellino, R., Boido, M., Borsello, T. & Vercelli, A. Pharmacological c-Jun NH2-terminal kinase (JNK) pathway inhibition reduces severity of spinal muscular atrophy disease in mice. Front Mol Neurosci 11, 1\u201315 (2018).","journal-title":"Front Mol Neurosci"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2018.00017","volume":"12","author":"M Boido","year":"2018","unstructured":"Boido, M. et al. Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy. Front Cell Neurosci 12, 1\u201314 (2018).","journal-title":"Front Cell Neurosci"},{"key":"1689_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0128560","volume":"10","author":"V Valsecchi","year":"2015","unstructured":"Valsecchi, V., Boido, M., De Amicis, E., Piras, A. & Vercelli, A. Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model. PLoS ONE 10, 1\u201317 (2015).","journal-title":"PLoS ONE"},{"key":"1689_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0086-4","volume":"8","author":"A Piras","year":"2017","unstructured":"Piras, A. et al. Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy. Cell Death Dis 8, 3223 (2017).","journal-title":"Cell Death Dis"},{"key":"1689_CR25","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1096\/fj.13-248583","volume":"28","author":"X Gallart-Palau","year":"2014","unstructured":"Gallart-Palau, X. et al. Neuregulin-1 is concentrated in the postsynaptic subsurface cistern of C-bouton inputs to \u03b1-motoneurons and altered during motoneuron diseases. FASEB J 28, 3618\u20133632 (2014).","journal-title":"FASEB J"},{"key":"1689_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-023-01551-8","volume":"11","author":"L Kong","year":"2023","unstructured":"Kong, L. et al. Boosting neuregulin 1 type-III expression hastens SMA motor axon maturation. Acta Neuropathol Commun 11, 53 (2023).","journal-title":"Acta Neuropathol Commun"},{"key":"1689_CR27","doi-asserted-by":"publisher","first-page":"e19090","DOI":"10.1371\/journal.pone.0019090","volume":"6","author":"J Ackermann","year":"2011","unstructured":"Ackermann, J. et al. Loss of ATF2 function leads to cranial motoneuron degeneration during embryonic mouse development. PLoS ONE 6, e19090 (2011).","journal-title":"PLoS ONE"},{"key":"1689_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbi.2024.01.004","volume":"117","author":"EF Willis","year":"2024","unstructured":"Willis, E. F. et al. ROCK2 regulates microglia proliferation and neuronal survival after traumatic brain injury. Brain Behav Immun 117, 181\u2013194 (2024).","journal-title":"Brain Behav Immun"},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fonc.2014.00197","volume":"4","author":"P Obexer","year":"2014","unstructured":"Obexer, P. & Ausserlechner, M. J. X-linked inhibitor of apoptosis protein \u2014 a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol 4, 197 (2014).","journal-title":"Front Oncol"},{"key":"1689_CR30","first-page":"1177","volume":"15","author":"P Li","year":"2018","unstructured":"Li, P. et al. PDCD5 regulates cell proliferation, cell cycle progression and apoptosis. Oncol Lett 15, 1177\u20131183 (2018).","journal-title":"Oncol Lett"},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.3049","volume":"33","author":"Y Maury","year":"2015","unstructured":"Maury, Y. et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol 33, 89\u201396 (2015).","journal-title":"Nat Biotechnol"},{"key":"1689_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg6518","volume":"380","author":"M Arbab","year":"2023","unstructured":"Arbab, M. et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science 380, eadg6518 (2023).","journal-title":"Science"},{"key":"1689_CR33","doi-asserted-by":"publisher","first-page":"E2347","DOI":"10.1073\/pnas.1613181114","volume":"114","author":"M Jangi","year":"2017","unstructured":"Jangi, M. et al. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage. Proc Natl Acad Sci USA 114, E2347\u2013E2356 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jphs.2020.09.001","volume":"144","author":"S Ando","year":"2020","unstructured":"Ando, S. et al. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy. J Pharmacol Sci 144, 204\u2013211 (2020).","journal-title":"J Pharmacol Sci"},{"key":"1689_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13581-z","volume":"7","author":"H Morrison","year":"2017","unstructured":"Morrison, H., Young, K., Qureshi, M., Rowe, R. K. & Lifshitz, J. Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury. Sci Rep 7, 13211 (2017).","journal-title":"Sci Rep"},{"key":"1689_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02191-2","volume":"18","author":"M MacLean","year":"2021","unstructured":"MacLean, M. et al. Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1(G93A) murine model of amyotrophic lateral sclerosis in a sex-dependent manner. J Neuroinflamm 18, 139 (2021).","journal-title":"J Neuroinflamm"},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","volume":"78","author":"C Missale","year":"1998","unstructured":"Missale, C., Nash, S. R., Robinson, S. W., Jaber, M. & Caron, M. G. Dopamine receptors: from structure to function. Physiol Rev 78, 189\u2013225 (1998).","journal-title":"Physiol Rev"},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0028-3908(98)00215-9","volume":"38","author":"S Balijepalli","year":"1999","unstructured":"Balijepalli, S., Boyd, M. R. & Ravindranath, V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 38, 567\u2013577 (1999).","journal-title":"Neuropharmacology"},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1007\/s00018-021-03819-5","volume":"78","author":"R James","year":"2021","unstructured":"James, R., Chaytow, H., Ledahawsky, L. M. & Gillingwater, T. H. Revisiting the role of mitochondria in spinal muscular atrophy. Cell Mol Life Sci 78, 4785\u20134804 (2021).","journal-title":"Cell Mol Life Sci"},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"10878","DOI":"10.3390\/ijms231810878","volume":"23","author":"E Zilio","year":"2022","unstructured":"Zilio, E., Piano, V. & Wirth, B. Mitochondrial dysfunction in spinal muscular atrophy. Int J Mol Sci 23, 10878 (2022).","journal-title":"Int J Mol Sci"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/exnr.1994.1207","volume":"130","author":"CA Fox","year":"1994","unstructured":"Fox, C. A., Mansour, A. & Watson, S. J. J. The effects of haloperidol on dopamine receptor gene expression. Exp Neurol 130, 288\u2013303 (1994).","journal-title":"Exp Neurol"},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0014-2999(90)90260-D","volume":"177","author":"WD Bowen","year":"1990","unstructured":"Bowen, W. D., Moses, E. L., Tolentino, P. J. & Walker, J. M. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur J Pharmacol 177, 111\u2013118 (1990).","journal-title":"Eur J Pharmacol"},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"105366","DOI":"10.1016\/j.nbd.2021.105366","volume":"155","author":"A Sansa","year":"2021","unstructured":"Sansa, A., de la Fuente, S., Comella, J. X., Garcera, A. & Soler, R. M. Intracellular pathways involved in cell survival are deregulated in mouse and human spinal muscular atrophy motoneurons. Neurobiol Dis 155, 105366 (2021).","journal-title":"Neurobiol Dis"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1007\/s10528-023-10657-6","volume":"62","author":"ANH Abd El Mutaleb","year":"2024","unstructured":"Abd El Mutaleb, A. N. H. et al. NAIP gene deletion and SMN2 copy number as molecular tools in predicting the severity of spinal muscular atrophy. Biochem Genet 62, 5051\u20135072 (2024).","journal-title":"Biochem Genet"},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.pnpbp.2011.04.002","volume":"35","author":"B Pan","year":"2011","unstructured":"Pan, B., Huang, X.-F. & Deng, C. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35, 924\u2013930 (2011).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1689_CR46","doi-asserted-by":"publisher","unstructured":"Heckmann, B. L., Tummers, B. & Green, D. R. Crashing the computer: apoptosis vs. necroptosis in neuroinflammation. https:\/\/doi.org\/10.1038\/s41418-018-0195-3 (2019).","DOI":"10.1038\/s41418-018-0195-3"},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuint.2017.02.003","volume":"105","author":"DA Dalwadi","year":"2017","unstructured":"Dalwadi, D. A., Kim, S. & Schetz, J. A. Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. Neurochem Int 105, 21\u201331 (2017).","journal-title":"Neurochem Int"},{"key":"1689_CR48","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.3390\/ijms22094399","volume":"22","author":"V Racki","year":"2021","unstructured":"Racki, V., Marcelic, M., Stimac, I., Petric, D. & Kucic, N. Effects of haloperidol, risperidone, and aripiprazole on the immunometabolic properties of BV-2 microglial cells. Int J Mol Sci 22, 4399 (2021).","journal-title":"Int J Mol Sci"},{"key":"1689_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/metabo11070422","volume":"11","author":"Z Koshenov","year":"2021","unstructured":"Koshenov, Z. et al. Sigma-1 receptor promotes mitochondrial bioenergetics by orchestrating ER Ca(2+.) leak during early ER stress. Metabolites 11, 422 (2021).","journal-title":"Metabolites"},{"key":"1689_CR50","doi-asserted-by":"publisher","first-page":"113622","DOI":"10.1016\/j.celrep.2023.113622","volume":"43","author":"J Lai","year":"2024","unstructured":"Lai, J. et al. ATM-deficiency-induced microglial activation promotes neurodegeneration in ataxia-telangiectasia. Cell Rep 43, 113622 (2024).","journal-title":"Cell Rep"},{"key":"1689_CR51","doi-asserted-by":"publisher","first-page":"6378","DOI":"10.1523\/JNEUROSCI.0774-19.2019","volume":"39","author":"X Song","year":"2019","unstructured":"Song, X., Ma, F. & Herrup, K. Accumulation of cytoplasmic DNA due to ATM deficiency activates the microglial viral response system with neurotoxic consequences. J Neurosci 39, 6378\u20136394 (2019).","journal-title":"J Neurosci"},{"key":"1689_CR52","doi-asserted-by":"publisher","unstructured":"D\u2019Errico, P. et al. Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0082654 (2013).","DOI":"10.1371\/journal.pone.0082654"},{"key":"1689_CR53","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/0883073809332702","volume":"24","author":"J Montes","year":"2009","unstructured":"Montes, J., Gordon, A. M., Pandya, S., De Vivo, D. C. & Kaufmann, P. Clinical outcome measures in spinal muscular atrophy. J Child Neurol 24, 968\u2013978 (2009).","journal-title":"J Child Neurol"},{"key":"1689_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00415-025-13005-3","volume":"272","author":"SV Fr\u00f8lich","year":"2025","unstructured":"Fr\u00f8lich, S. V., Receveur, N., Poulsen, N. S., Hansen, A. E. & Vissing, J. Whole-body muscle MRI in patients with spinal muscular atrophy. J Neurol 272, 271 (2025).","journal-title":"J Neurol"},{"key":"1689_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.neuron.2010.12.032","volume":"69","author":"GZ Mentis","year":"2011","unstructured":"Mentis, G. Z. et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 69, 453\u2013467 (2011).","journal-title":"Neuron"},{"key":"1689_CR56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1194\/jlr.M026948","volume":"54","author":"A Canfr\u00e1n-Duque","year":"2013","unstructured":"Canfr\u00e1n-Duque, A. et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54, 310\u2013324 (2013).","journal-title":"J Lipid Res"},{"key":"1689_CR57","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1111\/bph.13067","volume":"172","author":"RJ van der Sluis","year":"2015","unstructured":"van der Sluis, R. J., Nahon, J. E., Reuwer, A. Q., Van Eck, M. & Hoekstra, M. Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice. Br J Pharmacol 172, 2397\u20132405 (2015).","journal-title":"Br J Pharmacol"},{"key":"1689_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci11020131","volume":"11","author":"KS Watson","year":"2021","unstructured":"Watson, K. S., Boukhloufi, I., Bowerman, M. & Parson, S. H. The relationship between body composition, fatty acid metabolism and diet in spinal muscular atrophy. Brain Sci 11, 1\u201314 (2021).","journal-title":"Brain Sci"},{"key":"1689_CR59","unstructured":"Human Protein Atlas. DRD2 tissue expression. https:\/\/www.proteinatlas.org\/ENSG00000149295-DRD2\/tissue (accessed March 2026)."},{"key":"1689_CR60","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.3390\/ijms24055042","volume":"24","author":"J Neumann","year":"2023","unstructured":"Neumann, J., Hofmann, B., Dhein, S. & Gergs, U. Role of Dopamine in the Heart in Health and Disease. Int J Mol Sci 24, 5042 (2023).","journal-title":"Int J Mol Sci"},{"key":"1689_CR61","doi-asserted-by":"publisher","first-page":"115147","DOI":"10.1016\/j.celrep.2024.115147","volume":"44","author":"JG Pagiazitis","year":"2025","unstructured":"Pagiazitis, J. G. et al. Catecholaminergic dysfunction drives postural and locomotor deficits in a mouse model of spinal muscular atrophy. Cell Rep 44, 115147 (2025).","journal-title":"Cell Rep"},{"key":"1689_CR62","doi-asserted-by":"publisher","first-page":"8703","DOI":"10.1523\/JNEUROSCI.0204-12.2012","volume":"32","author":"TL Martinez","year":"2012","unstructured":"Martinez, T. L. et al. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. J Neurosci 32, 8703\u20138715 (2012).","journal-title":"J Neurosci"},{"key":"1689_CR63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","volume":"10","author":"M Boido","year":"2016","unstructured":"Boido, M. & Vercelli, A. Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy. Front Neuroanat 10, 6 (2016).","journal-title":"Front Neuroanat"},{"key":"1689_CR64","first-page":"1","volume":"7","author":"AJ-H Lee","year":"2012","unstructured":"Lee, A. J.-H., Awano, T., Park, G.-H. & Monani, U. R. Limited phenotypic effects of selectively augmenting the SMN protein in the neurons of a mouse model of severe spinal muscular atrophy. PLoS ONE 7, 1\u201310 (2012).","journal-title":"PLoS ONE"},{"key":"1689_CR65","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3, 72ra18 (2011).","journal-title":"Sci Transl Med"},{"key":"1689_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier, A. et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 6, 1\u201312 (2018).","journal-title":"Pharmacol Res Perspect"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01689-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:02:40Z","timestamp":1782716560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01689-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01689-0","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B., C.M., R.A., C.J., P.K., and G.M. are co-inventors in patent application WO2023118164A1 (\u201cHaloperidol for use in the treatment of spinal muscular atrophy\u201d). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}